share_log

Bristol-Myers Squibb | 4: Statement of changes in beneficial ownership of securities-Officer Caforio Giovanni

SEC announcement ·  Mar 13 05:44
Summary by Futu AI
On March 10, 2024, Giovanni Caforio, Executive Chair of the Board at Bristol-Myers Squibb (BMY), completed a series of transactions involving the company's common stock. Caforio acquired a total of 190,130 shares through the exercise or conversion of derivative securities at no cost. Concurrently, he disposed of 125,359 shares, with a portion of the disposals being used to cover exercise prices or tax liabilities at a price of $53.79 per share. The total market value of the disposed shares amounted to $3,648,199.17. Following these transactions, Caforio directly holds 432,266.333 shares of Bristol-Myers Squibb common stock.
On March 10, 2024, Giovanni Caforio, Executive Chair of the Board at Bristol-Myers Squibb (BMY), completed a series of transactions involving the company's common stock. Caforio acquired a total of 190,130 shares through the exercise or conversion of derivative securities at no cost. Concurrently, he disposed of 125,359 shares, with a portion of the disposals being used to cover exercise prices or tax liabilities at a price of $53.79 per share. The total market value of the disposed shares amounted to $3,648,199.17. Following these transactions, Caforio directly holds 432,266.333 shares of Bristol-Myers Squibb common stock.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.